Effect and Safety of Meropenem–Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial

Infectious Diseases and Therapy

Volumn 7, Issue 4, 2018, Pages 439-455

  Wunderink, Richard G ^a   Giamarellos Bourboulis, Evangelos J ^b   Rahav, Galia ^c   Mathers, Amy J ^d   Bassetti, Matteo ^e   Vazquez, Jose ^f   Cornely, Oliver A ^g   Solomkin, Joseph ^h   Bhowmick, Tanaya ⁱ   Bishara, Jihad ^c   Daikos, George L ^j   Felton, Tim ^k   Furst, Maria Jose Lopez ^l   Kwak, Eun Jeong ^m   Menichetti, Francesco ⁿ   Oren, Ilana ^o   Alexander, Elizabeth L ^p   Griffith, David ^q   Lomovskaya, Olga ^q   Loutit, Jeffery ^q   Zhang, Shu ^p   Dudley, Michael N ^q   Kaye, Keith S ^r   more..

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c TEL AVIV UNIVERSITY   (Israel)

^d UNIVERSITY OF VIRGINIA   (United States)

^e Azienda Sanitaria Universitaria Friuli Centrale   (Italy)

^f MEDICAL COLLEGE OF GEORGIA   (United States)

^g UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^h UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

ⁱ ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^j UNIVERSITY OF ATHENS   (Greece)

^k UNIVERSITY OF MANCHESTER   (United Kingdom)

^l Unidad B de Cirugia General   (Argentina)

^m UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

ⁿ UNIVERSITY HOSPITAL OF PISA   (Italy)

^o Unit of Infectious Diseases   (Israel)

^p MEDICINES COMPANY   (United States)

^q Medicines Company   (United States)

^r UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

more..

Author keywords

Best available therapy; Carbapenem resistant Enterobacteriaceae; Meropenem vaborbactam; Randomized clinical trial; TANGO II

Indexed keywords

AMINOGLYCOSIDE; AVIBACTAM PLUS CEFTAZIDIME; CARBAPENEM; CREATININE; MEROPENEM PLUS VABORBACTAM; POLYMYXIN; TIGECYCLINE;

ACUTE KIDNEY FAILURE; ADULT; ANEMIA; ANTIMICROBIAL THERAPY; ARTICLE; BACTEREMIA; BACTERIUM ISOLATION; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; CONTROLLED STUDY; DIARRHEA; DISK DIFFUSION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENTEROBACTERIACEAE INFECTION; FEMALE; HUMAN; HYPOKALEMIA; HYPOTENSION; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MALE; MIC50; MONOTHERAPY; MORTALITY; MULTICENTER STUDY; NEPHROTOXICITY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SEPTIC SHOCK; TREATMENT FAILURE;

EID: 85056120314     PISSN: 21938229     EISSN: 21936382     Source Type: Journal    
DOI: 10.1007/s40121-018-0214-1     Document Type: Article

References (30)

1. Bassetti M, Poulakou G, Ruppe E, Bouza E, Van Hal SJ, Brink A. Antimicrobial resistance in the next 30 years, humankind, bugs and drugs: a visionary approach. Intensive Care Med. 2017. 10.1007/s00134-017-4878
2. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. https://www.cdc.gov/drugresistance/threat-report-2013/index.html. Accessed 27 Aug 2017
3. World Health Organization. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. http://www.who.int/medicines/publications/global-priority-list-antibiotic-resistant-bacteria/en/. Accessed 5 Sep 2017
4. European Commission. A European One Health action plan against antimicrobial resistance (AMR). https://ec.europa.eu/health/amr/action_eu_en. Accessed 5 Sep 2017
5. The Pew Charitable Trusts. GAIN: how a new law is stimulating the development of antibiotics. http://www.pewtrusts.org/en/research-and-analysis/issue-briefs/2013/11/07/gain-how-a-new-law-is-stimulating-the-development-of-antibiotics. Accessed 5 Sep 2017
6. O’Neill J. Tackling drug-resistant infections globally: an overview of our work. The review on antimicrobial resistance. London: Wellcome Trust; 2016
7. Pitout JD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis. 2008;8(3):159–66
8. Munoz-Price LS, Poirel L, Bonomo RA, et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis. 2013;13(9):785–96
9. Giacobbe DR, Del Bono V, Trecarichi EM, et al; ISGRI-SITA (Italian Study Group on Resistant Infections of the Società Italiana Terapia Antinfettiva). Risk factors for bloodstream infections due to colistin-resistant KPC-producing Klebsiella pneumoniae: results from a multicenter case-control-control study. Clin Microbiol Infect. 2015;21(12):1106.e1–1106.e8
10. Monaco M, Giani T, Raffone M, et al. Colistin resistance superimposed to endemic carbapenem-resistant Klebsiella pneumoniae: a rapidly evolving problem in Italy, November 2013 to April 2014. Euro Surveill. 2014;19(42):14–8
11. Shields RK, Chen L, Cheng S, et al Emergence of ceftazidime-avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections. Antimicrob Agents Chemother. 2017;61(3):3e02097-16-3e020916
12. Alexander EL, Loutit J, Tumbarello M, et al. Carbapenem-resistant Enterobacteriaceae infections: results from a retrospective series and implications for the design of prospective clinical trials. Open Forum Inf Dis. 2017;4(2):ofx063
13. Falagas ME, Lourida P, Poulikakos P, Rafailidis PI, Tansarli GS. Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae: systematic evaluation of the available evidence. Antimicrob Agents Chemother. 2014;58(2):654–63
14. Tumbarello M, Viale P, Viscoli C, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis. 2012;55(7):943–50
15. Daikos GL, Tsaousi S, Tzouvelekis LS, et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother. 2014;58(4):2322–8
16. Pouch SM, Satlin MJ. Carbapenem-resistant Enterobacteriaceae in special populations: solid organ transplant recipients, stem cell transplant recipients, and patients with hematologic malignancies. Virulence. 2017;8(4):391–402
17. Hecker SJ, Reddy KR, Totrov M, et al. Discovery of a cyclic boronic acid beta-lactamase inhibitor (RPX7009) with utility vs. class A serine carbapenemases. J Med Chem. 2015;58(9):3682–92
18. Rubino CM, Bhavnani SM, Loutit JS, Morgan EE, White D, Dudley MN, Griffith DC (2018) Phase 1 study of the safety, tolerability, and pharmacokinetics of vaborbactam and meropenem alone and in combination following single and multiple doses in healthy adult subjects. Antimicrob Agents Chemother. 10.1128/AAC.02228-17
19. Kaye KS, Bhowmick T, Metallidis S, et al. Effect of meropenem–vaborbactam vs. piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: the TANGO I randomized clinical trial. JAMA. 2018;319(8):788–99
20. FDA approves new antibacterial drug [press release]. Silver Spring, MD: US Food and Drug Administration; August 29, 2017. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm573955.htm. Accessed 3 Sep 2017
21. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13(10):818–29
22. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Wayne: Clinical and Laboratory Standards Institute; 2014
23. European Committee on Antimicrobial Susceptibility Testing. Antimicrobial susceptibility testing. 2014. http://www.eucast.org/ast_of_bacteria/. Accessed 27 Aug 2017
24. US Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE). https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm. Accessed 27 Aug 2017
25. Bellomo R, Kellum J, Ronco C. Acute renal failure: time for consensus. Intensive Care Med. 2001;27(11):1685–8
26. Tumbarello M, Trecarichi EM, De Rosa FG, et al. ISGRI-SITA (Italian Study Group on Resistant Infections of the Società Italiana Terapia Antinfettiva). Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. J Antimicrob Chemother. 2015;70(7):2133–43
27. Daikos GL, Petrikkos P, Psichogiou M, et al. Prospective observational study of the impact of VIM-1 metallo-beta-lactamase on the outcome of patients with Klebsiella pneumoniae bloodstream infections. Antimicrob Agents Chemother. 2009;53(5):1868–73
28. Cerqueira GC, Earl AM, Ernst CM, et al. Multi-institute analysis of carbapenem resistance reveals remarkable diversity, unexplained mechanisms, and limited clonal outbreaks. Proc Natl Acad Sci USA. 2017;114(5):1135–40
29. Glasner C, Albiger B, Buist G, et al Carbapenemase-producing Enterobacteriaceae in Europe: a survey among national experts from 39 countries, February 2013. Euro Surveill. 2013;18(28):20525. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20525. Accessed 27 Aug 2017
30. Lewis SJ, Mueller BA. Antibiotic dosing in patients with acute kidney injury: ‘enough but not too much’. J Intensive Care Med. 2014;31(3):164–76